No 'Unicorn' High-Cost/High-Volume Drugs Expected For 2017
Executive Summary
Specialty drugs, which have been a key driver of health care spending growth in years past, are not expected to have the same impact in 2017 – mostly because there's no "unicorn" high-cost, high-volume blockbusters, like the hepatitis C virus medicines Sovaldi and Harvoni, marketed by Gilead Sciences Inc., and Viekira Pak, sold by AbbVie Inc., anticipated to enter the market next year.
You may also be interested in...
Senators Fear Viral Spread Of Gilead Pricing Strategy
While it was Gilead Sciences Inc.'s hepatitis C virus (HCV) treatments Sovaldi (sofosbuvir) and Harvoni (ledipasvir-sofosbuvir) that was at the center of a bipartisan congressional investigation into how the company priced those drugs, the concern by the lawmakers who initiated the probe was what would happen if the company's approach is adopted by other firms selling blockbuster specialty medicines for Alzheimer's, cancer, diabetes and HIV.
Express Scripts Repatha, Praluent Deals: What It Means
After all the handwringing about whether payers would cover the newly approved proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors Praluent (alirocumab), marketed by Sanofi SA and Regeneron Pharmaceuticals Inc., and Repatha (evolocumab), from Amgen Inc., Express Scripts Holding Co., the largest pharmacy benefit management (PBM) company in the US, said it has sealed deals for both drugs – declaring it has scored discounts on the medicines, which means neither will be excluded from its formulary.
CVS takes aim at PCSK9s; costs could dwarf HCV meds
Forget Sovaldi's $1,000-per-pill price.